Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385408060> ?p ?o ?g. }
- W4385408060 endingPage "114609" @default.
- W4385408060 startingPage "114609" @default.
- W4385408060 abstract "Parkinson's disease is one of the most common neurodegenerative diseases. Excellent levodopa responsiveness has been proposed as a characteristic supporting feature in substantiating the PD diagnosis. However, a small portion of clinically established PD patients shows poor levodopa response. This study aims to investigate brain function alterations of PD patients with poor levodopa responsiveness by PET/MRI. A total of 46 PD patients were recruited. They all completed 11C-CFT PET/MRI scans and the acute levodopa challenge test. Among these 46 PD patients, 42 participants further underwent 18F-FDG PET/MRI scans. Clinical variables regarding demographic data, disease features and cognition scales were also collected. Based on the improvement rate of UPDRS‐III, PD patients were divided into non-responders (improvement rate < 33%) and responders (improvement rate ≥ 33%). Statistical parametric zapping was performed to analyze molecular imaging. Dopaminergic uptake and metabolism of 70 brain regions were converted to quantitative values and expressed as standard uptake value (SUV). SUV was further normalized by the cerebellum. The resulting SUV ratios and clinical variables were then compared by SPSS. The difference between levodopa non-responders (n=17) and responders (n=29) in the UPDRS III baseline was statistically significant and the former had a lower UPDRS III baseline (19 (10, 32), p＜0.05). In contrast, no statistical difference between these two groups was found in age, gender, disease duration, cognition, motor subtype and Hoehn-Yahr stage. Dopaminergic uptake differences between levodopa non-responders (n = 17) and responders (n = 29) were shown in the left inferior frontal cortex (1.00 ± 0.09 vs 1.07 ± 0.08, p < 0.05 and FDR < 0.2), the right posterior cingulum (1.10 ± 0.10 vs 1.20 ± 0.13, p <0.05 and FDR < 0.2) and the right insula (1.21 ± 0.12 vs 1.30 ± 0.10, p < 0.05 and FDR < 0.2). The metabolic alterations between levodopa non-responders (n=16) and responders (n=26) were shown in the right supplementary motor area (1.30 (1.18, 1.39) vs 1.41 (1.31, 1.53), p < 0.05 and FDR < 0.2), right precuneus (1.37 ± 0.10 vs 1.47 ± 0.18, p < 0.05 and FDR < 0.2), right parietal cortex (1.14 ± 0.15 vs 1.27 ± 0.21, p < 0.05 and FDR < 0.2), right supramarginal gyrus (1.16 (1.12, 1.26) vs 1.25 (1.14, 1.46), p < 0.05 and FDR < 0.2), right postcentral gyrus (1.15 (1.08, 1.32) vs 1.24 (1.17, 1.39), p < 0.05 and FDR < 0.2), medulla (0.75 ± 0.07 vs 0.80 ± 0.07, p < 0.05 and FDR < 0.2), right rolandic operculum (1.25 (1.18, 1.32) vs 1.33 (1.25, 1.50), p < 0.05 and FDR < 0.2), right olfactory (0.95 (0.91, 1.01) vs 1.01 (0.95, 1.15), p < 0.05 and FDR < 0.2), the right insula (1.15 (1.06, 1.22) vs 1.21 (1.12, 1.35), p < 0.05 and FDR < 0.2) and the left cerebellum crus (0.96 (0.91, 1.01) vs 0.92 (0.86, 0.96), p < 0.05 and FDR < 0.2). PD patients with poor response to levodopa showed less severe impairment of baseline motor symptoms, more severe dopaminergic deficits in the left inferior frontal, right posterior cingulate cortex and the right insula, and lower metabolism in the right supplementary motor area, right precuneus, right parietal cortex, right supramarginal gyrus, right postcentral gyrus, medulla, right rolandic operculum, right olfactory, the right insula and higher metabolism in the left cerebellum crus." @default.
- W4385408060 created "2023-08-01" @default.
- W4385408060 creator A5038145110 @default.
- W4385408060 creator A5042089527 @default.
- W4385408060 creator A5043974614 @default.
- W4385408060 creator A5064487358 @default.
- W4385408060 creator A5067536358 @default.
- W4385408060 creator A5083667570 @default.
- W4385408060 creator A5085557984 @default.
- W4385408060 date "2023-10-01" @default.
- W4385408060 modified "2023-10-18" @default.
- W4385408060 title "Integrated PET/MRI With 11C-CFT and 18F-FDG for levodopa response difference in Parkinson’s disease" @default.
- W4385408060 cites W1913030292 @default.
- W4385408060 cites W1963979144 @default.
- W4385408060 cites W1964373680 @default.
- W4385408060 cites W1998444969 @default.
- W4385408060 cites W1999066011 @default.
- W4385408060 cites W2004996958 @default.
- W4385408060 cites W2019182054 @default.
- W4385408060 cites W2032370847 @default.
- W4385408060 cites W2038618926 @default.
- W4385408060 cites W2048207814 @default.
- W4385408060 cites W2061553829 @default.
- W4385408060 cites W2067456724 @default.
- W4385408060 cites W2067565974 @default.
- W4385408060 cites W2069004548 @default.
- W4385408060 cites W2072141794 @default.
- W4385408060 cites W2073201795 @default.
- W4385408060 cites W2074957274 @default.
- W4385408060 cites W2086982304 @default.
- W4385408060 cites W2093465095 @default.
- W4385408060 cites W2096299066 @default.
- W4385408060 cites W2101249624 @default.
- W4385408060 cites W2102001229 @default.
- W4385408060 cites W2112455323 @default.
- W4385408060 cites W2117057382 @default.
- W4385408060 cites W2117381358 @default.
- W4385408060 cites W2119056409 @default.
- W4385408060 cites W2130974692 @default.
- W4385408060 cites W2147546041 @default.
- W4385408060 cites W2151204406 @default.
- W4385408060 cites W2284529870 @default.
- W4385408060 cites W2320175522 @default.
- W4385408060 cites W2344576266 @default.
- W4385408060 cites W2403629665 @default.
- W4385408060 cites W2510830118 @default.
- W4385408060 cites W2616834563 @default.
- W4385408060 cites W2620571758 @default.
- W4385408060 cites W2621721356 @default.
- W4385408060 cites W2759677505 @default.
- W4385408060 cites W2793390293 @default.
- W4385408060 cites W2800113075 @default.
- W4385408060 cites W2887672196 @default.
- W4385408060 cites W2945475603 @default.
- W4385408060 cites W2968828261 @default.
- W4385408060 cites W2972552150 @default.
- W4385408060 cites W3006829355 @default.
- W4385408060 cites W3037518324 @default.
- W4385408060 cites W3041850638 @default.
- W4385408060 cites W3130215473 @default.
- W4385408060 cites W3132192610 @default.
- W4385408060 cites W3156032615 @default.
- W4385408060 cites W3175447976 @default.
- W4385408060 cites W3195912326 @default.
- W4385408060 cites W4213412842 @default.
- W4385408060 cites W4233994114 @default.
- W4385408060 cites W4293843103 @default.
- W4385408060 cites W4309918597 @default.
- W4385408060 doi "https://doi.org/10.1016/j.bbr.2023.114609" @default.
- W4385408060 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37532003" @default.
- W4385408060 hasPublicationYear "2023" @default.
- W4385408060 type Work @default.
- W4385408060 citedByCount "0" @default.
- W4385408060 crossrefType "journal-article" @default.
- W4385408060 hasAuthorship W4385408060A5038145110 @default.
- W4385408060 hasAuthorship W4385408060A5042089527 @default.
- W4385408060 hasAuthorship W4385408060A5043974614 @default.
- W4385408060 hasAuthorship W4385408060A5064487358 @default.
- W4385408060 hasAuthorship W4385408060A5067536358 @default.
- W4385408060 hasAuthorship W4385408060A5083667570 @default.
- W4385408060 hasAuthorship W4385408060A5085557984 @default.
- W4385408060 hasConcept C126322002 @default.
- W4385408060 hasConcept C126838900 @default.
- W4385408060 hasConcept C137183658 @default.
- W4385408060 hasConcept C143409427 @default.
- W4385408060 hasConcept C143998085 @default.
- W4385408060 hasConcept C15744967 @default.
- W4385408060 hasConcept C199374082 @default.
- W4385408060 hasConcept C2775842073 @default.
- W4385408060 hasConcept C2779134260 @default.
- W4385408060 hasConcept C2779734285 @default.
- W4385408060 hasConcept C2780304432 @default.
- W4385408060 hasConcept C2989005 @default.
- W4385408060 hasConcept C39313694 @default.
- W4385408060 hasConcept C513476851 @default.
- W4385408060 hasConcept C60592354 @default.
- W4385408060 hasConcept C71924100 @default.
- W4385408060 hasConceptScore W4385408060C126322002 @default.